Clinical trials: AD
Atopic Dermatitis
A Phase I Clinical Trial to Evaluate CU-10101 Unguent
The study was conducted in two parts:Part 1 and Part 2.Part 1 is a single-site,randomized,double-blind,vehicle-controlled single and multiple administration,dose-escalation study in healthy Chinese participants.There are four…
- Trial name
- NCT06744569
- Testing
- CU-10101
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Cortico Basal Degeneration, Corticobasal Syndrome
Imaging Studies in Corticobasal Syndrome
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other.
- Conditions
- Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration
- Trial name
- I-CAN (NCT07000851)
- Testing
- C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jennifer Whitwell
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Alzheimer Disease, Dementia of Alzheimer Type
Assess Fibrin in Brains With AD/ADRD
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
- Trial name
- NCT05336695
- Testing
- PET/MR Imaging, 64Cu-FBP8
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Anxiety, Healthy Volunteers
Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
Background: Research has shown that anxiety affects more than feelings. It also affects behavior. Researchers want to learn how the brain and body respond to unexpected threats.
- Trial name
- NCT05092971
- Testing
- Shock or startle device
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Demyelinating Disorders, MCI
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
The overall objective is to obtain an assessment of the pharmacokinetics of [18F]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple…
- Conditions
- Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis)
- Trial name
- NCT06999434
- Testing
- [ 18F]3F4AP, [18F]MK6240, [11C]PIB
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Yale University
Alzheimer s Disease
TSPO Modulation in AD
The aim of this study is to determine whether pharmacological modulation of TSPO (with XBD173, 90mg twice daily, orally, for 28 days) improves neurovascular coupling (NVC) in AD relative to placebo.
- Trial name
- NCT07191821
- Testing
- XBD173
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy…
- Trial name
- NCT07235384
- Testing
- ZL-1503
- Where
- 12 sites in Australia, China and 1 more
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Atopic Dermatitis
Pre-SunBeam TEWL AUC
Transepidermal Water Loss (TEWL) measurements are a valuable tool to determine the integrity of a person's skin barrier. In patients with skin conditions, like atopic dermatitis, skin barrier can be disrupted or weakened, leading…
- Trial name
- NCT04226092
- Testing
- GPSkin Barrier Pro, Aquaflux AF200
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Atopic Dermatitis
Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis
Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease inducing poor quality of life. Its conventional treatments often cause unsatisfactory relief and adverse effects in long-term application.
- Trial name
- NCT02844452
- Testing
- Acupuncture
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kyunghee University
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight
The Effect of a Propionate Colon Release Form on ad Libitum Eating and Appetite Perception
The present study aims to investigate the effect of a standardized liquid breakfast containing a food grade propionate colon release form on ad libitum eating and appetite perception in healthy overweight humans using a…
- Trial name
- METABIOTIC (NCT04019951)
- Testing
- Ca-propionate 1 g, Ca-propionate 3 g
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Subjective Cognitive Decline, Preclinical Alzheimer's Disease
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
This study is affiliated to Sino Longitudinal Study on Cognitive Decline, SILCODE. To establish models of normal and pathological cognitive aging.To collect the longitudinal data of SCD population, to study the dynamic changes of…
- Trial name
- NCT03370744
- Testing
- Neuropsychological scale
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- XuanwuH 2
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease (AD)
Daridorexant for Alzheimer Disease Prevention
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease.
- Trial name
- PAD-DORA (NCT07213349)
- Testing
- Daridorexant 50 mg
- Where
- Canada
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Alzheimer's Disease
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
The study will investigate the possibility of detecting early signs of Alzheimer's disease using magnetic resonance imaging (MRI).
- Trial name
- NCT00413621
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer's Disease, Mild Cognitive Impairment
Evolution of Memory Related Activity
The purpose of this study is to begin the process of validating fMRI (functional magnetic resonance imaging) as a biomarker for use in clinical trials and longitudinal studies of clinical progression in mild cognitive impairment…
- Trial name
- NCT00902499
- Where
- 2 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Mild Cognitive Impairment, Cognitive Decline
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment…
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Healthy Aging
- Trial name
- NCT03954899
- Testing
- melatonin
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Natalie Denburg